Off-Label Promotion, Class Labeling Debated During Antidepressant Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
The congressional investigation into antidepressants could renew interest in how off-label promotion is regulated in the U.S
You may also be interested in...
Pfizer Zoloft Ad Cited By FDA For Omitting Suicide Risk
FDA's ad review division objects to an October print ad for the antidepressant that failed to mention the risk of suicidality and clinical worsening. The ad's brief summary referenced information from outdated labeling, the agency says.
Pfizer Zoloft Ad Cited By FDA For Omitting Suicide Risk
FDA's ad review division objects to an October print ad for the antidepressant that failed to mention the risk of suicidality and clinical worsening. The ad's brief summary referenced information from outdated labeling, the agency says.
FDA Expected To Review Antidepressant Advisory Cmte. Findings At House Hearing
House Commerce/Oversight Subcommittee convenes Sept. 23 to resume inquiry into antidepressant use in children, methods to handle safety data. FDA may also be questioned on clinical trial registries and off-label promotion.